Abstract：Objective To investigate the status of drug resistance before anti-retroviral therapy among newly dignosed HIV/AIDS patients aged ≥50 years in Yangzhou City, Jiangsu Province, so as to provide the evidence for improving the anti-retroviral therapy effect of AIDS. Methods HIV/AIDS patients aged ≥50 years who were newly dignosed in Yangzhou City from 2021 to 2024 and did not receive anti-retroviral therapy were selected. Basic information were collected through the Chinese Disease Prevention and Control Information System. Blood samples were collected to determine CD4+T lymphocyte (CD4 cell) counts and HIV-1 viral load. Following nucleic acid extraction, the pol gene region was amplified using reverse transcription and nested PCR, and subsequently subjected to Sanger sequencing. The resulting sequences were uploaded to the Stanford University HIV Drug Resistance Database to analyze drug resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and nucleoside reverse transcriptase inhibitors (NRTIs). Results Totally 404 blood samples from HIV/AIDS patients were collected, with successful sequencing of the pol gene region in 341 cases. Among them, 253 (74.19%) were males and 88 (25.81%) were females, with a mean age of (62.48±7.60) years. A total of 152 cases (44.57%) had CD4 cell counts below 200 cells/μL, and 296 cases (86.80%) had HIV-1 viral loads exceeding 5 000 copies/mL. A total of 87 cases exhibited drug resistance-associated mutations, corresponding to a mutation rate of 25.51%. The predominant mutation site was V179, with a mutation rate of 17.01%. A total of 29 cases exhibited resistance to at least one drug, resulting in a resistance rate of 8.50%. The resistance rates to NNRTIs, PIs, and NRTIs were 5.57%, 2.93%, and 1.17%, respectively. The HIV/AIDS patients exhibited varying degrees of resistance to 13 anti-retroviral drugs, with low- or intermediate-level drug resistance being predominant. High-level drug resistance cases were observed against NNRTIs such as nevirapine and efavirenz. Conclusions The drug resistance rate before anti-retroviral therapy among newly dignosed HIV/AIDS patients aged ≥50 years in Yangzhou City was at a moderate level. The predominant resistance mutation was observed at V179 site, with NNRTIs resistance being most prevalent, primarily demonstrating low- or intermediate-level drug resistance.
[1] 张晗希,韩孟杰,周郁,等.我国50岁及以上人群HIV感染率的Meta分析[J].中华流行病学杂志,2020,41(1):96-102. ZHANG H X,HAN M J,ZHOU Y,et al.HIV infection rate in people aged 50 years and older in China:a Meta-analysis[J].Chin J Epidemiol,2020,41(1):96-102.(in Chinese) [2] TRICKEY A,SABIN C A,BURKHOLDER G,et al.Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America:a collaborative analysis of cohort studies[J].Lancet HIV,2023,10(5):295-307. [3] HOU Y S,JIN Y C,CAI C,et al.Comparative analysis of epidemiological features of HIV/AIDS cases aged over and under 50 years old-China,2010-2022[J].China CDC Weekly,2023,5(48):1079-1083. [4] 朱传新,郑文力,金聪囡,等.温州市新报告HIV-1感染者治疗前耐药分析[J].预防医学,2021,33(5):446-450. ZHU C X,ZHENG W L,JIN C N,et al.Pre-treatment drug resistance of newly reported HIV-1 infected individuals in Wenzhou[J].China Prev Med J,2021,33(5):446-450.(in Chinese) [5] CHEN H L,HU J,SONG C,et al.Molecular transmission network of pretreatment drug resistance among human immunodeficiency virus-positive individuals and the impact of virological failure on those who received antiretroviral therapy in China[J/OL].Front Med(Lausanne),2022,9[2025-07-07].https://doi.org/10.3389/fmed.2022.965836. [6] 中国疾病预防控制中心性病艾滋病预防控制中心.HIV-1基因型耐药检测及质量保证指南(2013年版)[M].北京:2013. National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention.Guideline for HIV-1 genotyping drug resistance testing and quality assurance(2013 edition)[M].Beijing:2013.(in Chinese) [7] 徐莉,黄九如,刘萍,等.扬州地区人类免疫缺陷病毒感染者治疗前基因亚型及耐药分析[J].临床检验杂志,2025,43(4):300-303. XU L,HUANG J R,LIU P,et al.Genetic subtypes and pretreatment drug resistance among HIV-1 individuals in Yangzhou,China[J].Chin J Clin Lab Sci,2025,43(4):300-303.(in Chinese) [8] 沈忠银. 中国艾滋病诊疗指南(2024版)[J].中国艾滋病性病,2024,30(8):779-805. SHEN Z Y.Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome(2024 edition)[J].Chin J AIDS STD,2024,30(8):779-805.(in Chinese) [9] SEVERIN S,DELFORGE M,DE WIT S.Epidemiology,comorbidities at diagnosis and outcomes associated with HIV late diagnosis from 2010 to 2019 in a Belgian reference centre:a retrospective study[J].HIV Med,2022,23(11):1184-1194. [10] 李韩平,李林,李敬云.HIV耐药毒株传播的监测[J].中国热带医学,2024,24(1):6-11. LI H P,LI L,LI J Y.Surveillance of HIV transmitted drug resistance[J].China Trop Med,2024,24(1):6-11.(in Chinese) [11] 吴玉灵,杨东智,李宗倍,等.2020年银川市HIV-1感染者基因亚型及耐药分析[J].病毒学报,2022,38(5):1160-1165. WU Y L,YANG D Z,LI Z B,et al.Characteristics of genotypes and drug resistance in HIV-infected patients in Yinchuan,2020,China[J].Chin J Virol,2022,38(5):1160-1165.(in Chinese) [12] 陈莉萍,卢静,周莹.全国第五次HIV分子流行病学调查江苏省新诊断感染者耐药及分子亚型分析[J].江苏预防医学,2025,36(1):19-21,25. CHEN L P,LU J,ZHOU Y.Analysis of drug resistance and molecular subtypes of newly diagnosed HIV infected individuals in Jiangsu Province from the fifth national HIV molecular epidemiology survey[J].Jiangsu J Prev Med,2025,36(1):19-21,25.(in Chinese) [13] World Health Organization.HIV drug resistance report2021[EB/OL].[2025-07-07].https://www.who.int/publications/i/item/9789240038608. [14] 陈素庭,洪航,许国章.抗病毒治疗的HIV/AIDS病例高血糖的影响因素分析[J].预防医学,2022,34(11):1110-1115,1120. CHEN S T,HONG H,XU G Z.Factors affecting hyperglycemia among HIV/AIDS patients receiving antiretroviral therapy[J].China Prev Med J,2022,34(11):1110-1115,1120.(in Chinese) [15] 吴斌,方琼楼,朱柯.金华市抗病毒治疗失败HIV/AIDS病例HIV-1亚型及耐药分析[J].预防医学,2024,36(6):506-509. WU B,FANG Q L,ZHU K.HIV-1 subtype and drug resistance in HIV/AIDS patients who failed in antiretroviral therapy in Jinhua City[J].China Prev Med J,2024,36(6):506-509.(in Chinese)
